Scholarlink

Introduction <p>Gastric carcinoma is a significant global health burden with diverse clinicopathological features and molecular alterations influencing prognosis and treatment. Human epidermal growth factor receptor 2 (HER2) overexpression is a critical biomarker in gastric carcinoma, guiding targeted therapeutic interventions. This study aimed to assess HER2 expression and its association with clinicopathological characteristics of gastric carcinoma.</p> Methods <p>A retrospective cross-sectional study was conducted using consecutive sampling to retrieve gastric carcinoma tissue blocks that met the inclusion criteria. A total of 136 formalin-fixed, paraffin-embedded tissue blocks from patients aged 18 years and above (2013–2023) at St. Francis Hospital Nsambya were analyzed. HER2 expression was evaluated using immunohistochemistry (IHC) with a standardized test kit. Associations between HER2 expression and demographic and histopathological characteristics were analyzed.</p> Results <p>Among 136 patients, the mean age was 59.63 years, with 48.53% aged 48–67 years. Most were male (63.24%) and from the Central region (60.70%). The intestinal subtype was the most common (78.68%), with 52.21% of tumors poorly differentiated, and tumors predominantly located in the antrum (32.35%), cardia (30.15%), and body (24.26%). Regarding HER2 expression, 11.76% were positive (3+), 2.21% equivocal (2+), and 86.03% negative (0 or 1+). HER2 positivity was significantly associated with residence in the Western region (aPR = 3.67; 95% CI: 1.33–10.11; <i>p</i> = 0.02) and with mixed-type tumors (aPR = 3.00; 95% CI: 1.70–5.30; <i>p</i> &lt; 0.001).</p> Conclusion <p>HER2 overexpression in gastric carcinoma was low. Nevertheless, the findings underscore the importance of routine HER2 testing and access to targeted therapy. Observed associations point to potential high-risk groups warranting further investigation in larger, multicenter studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human epidermal growth factor receptor 2 expression and socio-demographic, clinical, and histopathological characteristics in gastric carcinoma at St Francis Hospital Nsambya, Uganda

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Steven Wanda,
  • Gorretti Nassali,
  • Brian Bbosa,
  • Francis Basimbe,
  • Joviah Akulu,
  • Davis Nsamba,
  • Praise Nimusiima,
  • Joshua Muhumuza,
  • Emmanuel Othieno,
  • Maxwel Dancan Okuku

摘要

Introduction

Gastric carcinoma is a significant global health burden with diverse clinicopathological features and molecular alterations influencing prognosis and treatment. Human epidermal growth factor receptor 2 (HER2) overexpression is a critical biomarker in gastric carcinoma, guiding targeted therapeutic interventions. This study aimed to assess HER2 expression and its association with clinicopathological characteristics of gastric carcinoma.

Methods

A retrospective cross-sectional study was conducted using consecutive sampling to retrieve gastric carcinoma tissue blocks that met the inclusion criteria. A total of 136 formalin-fixed, paraffin-embedded tissue blocks from patients aged 18 years and above (2013–2023) at St. Francis Hospital Nsambya were analyzed. HER2 expression was evaluated using immunohistochemistry (IHC) with a standardized test kit. Associations between HER2 expression and demographic and histopathological characteristics were analyzed.

Results

Among 136 patients, the mean age was 59.63 years, with 48.53% aged 48–67 years. Most were male (63.24%) and from the Central region (60.70%). The intestinal subtype was the most common (78.68%), with 52.21% of tumors poorly differentiated, and tumors predominantly located in the antrum (32.35%), cardia (30.15%), and body (24.26%). Regarding HER2 expression, 11.76% were positive (3+), 2.21% equivocal (2+), and 86.03% negative (0 or 1+). HER2 positivity was significantly associated with residence in the Western region (aPR = 3.67; 95% CI: 1.33–10.11; p = 0.02) and with mixed-type tumors (aPR = 3.00; 95% CI: 1.70–5.30; p < 0.001).

Conclusion

HER2 overexpression in gastric carcinoma was low. Nevertheless, the findings underscore the importance of routine HER2 testing and access to targeted therapy. Observed associations point to potential high-risk groups warranting further investigation in larger, multicenter studies.